7-item list
7 myths about compounded semaglutide — fact-checked
Compounded semaglutide became widely available during the 2022-2025 FDA shortage and remains accessible through 503A compounding pharmacies in personalized formulations. Loud opinions outpace careful reading of the rules. Here's what is and is not true as of May 2026.
- 1
Myth: It's illegal now
FalseReality: Identical-copy compounding is no longer allowed since the shortage was declared resolved. Personalized formulations (different dose, added vitamin B12, etc.) remain legal through 503A pharmacies.
- 2
Myth: It's the same as Wegovy
FalseReality: The active ingredient is the same, but compounded versions differ in concentration, vehicle, and formulation. They are not FDA-approved drugs.
- 3
Myth: It's unsafe / unregulated
Partially falseReality: 503A pharmacies are state-licensed and follow USP compounding standards. Quality varies between compounders — ask your provider which pharmacy they use and request a recent certificate of analysis.
- 4
Myth: Brand is always better
NuancedReality: Brand-name Wegovy has more clinical trial data and standardized dosing. For patients without insurance who would otherwise go without treatment, well-sourced compounded semaglutide is reasonable.
- 5
Myth: Telehealth providers don't check your medical history
FalseReality: Licensed clinicians review intake forms and prescribe based on standard criteria. Required: BMI, comorbidities, contraindications. Provider quality varies — see our ranking.
- 6
Myth: You can't switch from compounded to brand
FalseReality: Most patients switch successfully. Coordinate with your prescriber to plan the dose transition (compounded dosing is sometimes weight-based rather than fixed-dose).
- 7
Myth: Insurance never covers compounded
Mostly trueReality: Insurance rarely covers compounded GLP-1s. A few HSA/FSA-eligible providers and some PA programs allow reimbursement; ask your specific plan.
Next step